Sexual Wellness Chart Documentation & Informed Consent Toolkit

Establishing a thorough medical baseline is essential before initiating any therapeutic protocol in sexual wellness. Intakes must capture systemic vascular health, endocrine balance, neurological factors, and prior pelvic or urologic surgeries. Standardized questionnaires—such as the International Index of Erectile Function (IIEF-5) for male patients or the Female Sexual Function Index (FSFI) for female patients—provide objective baseline metrics to evaluate subjective symptom severity.

Clinicians should systematically reconcile current medications, with focused attention on anticoagulants, antiplatelet agents, anti-hypertensives, and nitrates. Documenting lifestyle factors, such as smoking status and metabolic health, helps contextualize patient candidacy and set clinical expectations. Integrating these intake parameters across your specialty service line ensures consistent patient selection.

Chart notes must reflect an objective physical examination tailored to the planned intervention. Document vital signs, baseline skin integrity, presence of scar tissue, anatomical anomalies, or signs of localized infection at the intended treatment site. For male sexual wellness, record any evidence of Peyronie's plaques, fibrotic tissue, or vascular insufficiency.

When evaluating patients for protocols utilizing energy-based medical devices or injectable modalities, document tactile tissue compliance and pre-existing sensory deficits. Objective baseline physical findings provide important protection against post-procedure attribution of pre-existing anatomical variations.

Informed consent documents for regenerative sexual wellness procedures must clearly delineate procedure steps, expected recovery timelines, and known potential risks. Consent forms should specifically address transient pain, localized erythema, edema, ecchymosis, hematoma formation, infection, and potential non-responsiveness to treatment.

Where protocols involve autologous preparations or off-label applications of approved products within our biologics portfolio, explicit language regarding regulatory status and treatment rationale must be included. The consent workflow must document that the patient was provided sufficient time to review disclosures, discuss alternatives, and ask questions prior to the administration of topical or local anesthesia.

Procedure notes should follow a rigid format to ensure complete traceability. Capture specific product details, including manufacturer name, lot number, expiration date, yield volume, and processing parameters if autologous centrifugation is performed. Document local anesthetic agents used, including volume, concentration, and delivery technique.

Use precise anatomical descriptions or standardized charting diagrams to detail injection or application sites, depth, and volume per target vector. Document immediate post-procedure tissue response, patient tolerance, and confirmation that post-care instructions were reviewed and handed to the patient.

Structure your post-procedure charting to evaluate outcome trajectories at pre-determined follow-up intervals (e.g., 30, 60, and 90 days). Re-administer validated scoring tools during follow-up visits to track quantitative changes against pre-treatment baselines.

Establish a dedicated clinical incident reporting protocol for adverse events or non-standard recoveries. Document the onset, duration, management steps, and clinical resolution of any reported side effects to maintain thorough risk management records.